Factors Affecting Tamoxifen Metabolism in Patients With Breast Cancer: Preliminary Results of the French PHACS Study
| Autor: | Jacques Robert, Alicja Puszkiel, Alexandre Evrard, Etienne Chatelut, Florence Dalenc, Marc Debled, Fabienne Thomas, Caroline Delmas, Laurence Venat-Bouvet, Isabelle Sillet-Bach, Henri Roché, Thomas Filleron, Christelle Vachoux, Etienne Suc, Cécile Arellano, Jean-Christophe Boyer, Valérie Le Morvan, Melanie White-Koning, William Jacot |
|---|---|
| Přispěvatelé: | Centre de Recherches en Cancérologie de Toulouse (CRCT), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de Biochimie [CHRU Nîmes], Centre Hospitalier Régional Universitaire de Nîmes (CHRU Nîmes), Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Bergonié - CRLCC Bordeaux, CRLCC Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'Oncologie médicale [CHU Limoges], CHU Limoges, Clinique Saint Jean Languedoc, Centre Hospitalier Brive-la-Gaillarde, Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Institut Bergonié [Bordeaux], UNICANCER, Institut Claudius Regaud, Clinique Saint-Jean Languedoc [Toulouse] (CSJL) |
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Oncology
Adult medicine.medical_specialty CYP2D6 CYP2B6 Antineoplastic Agents Hormonal Genotype Breast Neoplasms [SDV.CAN]Life Sciences [q-bio]/Cancer CYP2C19 030226 pharmacology & pharmacy Polymorphism Single Nucleotide 03 medical and health sciences 0302 clinical medicine Breast cancer Pharmacokinetics Cytochrome P-450 Enzyme System Internal medicine medicine Cytochrome P-450 CYP3A Humans Pharmacology (medical) Prospective Studies skin and connective tissue diseases Aged Pharmacology CYP3A4 business.industry Middle Aged medicine.disease 3. Good health Cytochrome P-450 CYP2B6 Tamoxifen Cytochrome P-450 CYP2D6 Pharmacogenetics 030220 oncology & carcinogenesis Cytochrome P-450 CYP2C19 Inhibitors Female business medicine.drug |
| Zdroj: | Clinical Pharmacology and Therapeutics Clinical Pharmacology and Therapeutics, American Society for Clinical Pharmacology and Therapeutics, 2019, 106 (3), pp.585-595. ⟨10.1002/cpt.1404⟩ |
| ISSN: | 0009-9236 1532-6535 |
| DOI: | 10.1002/cpt.1404⟩ |
| Popis: | International audience; In addition to the effect of cytochrome P450 (CYP) 2D6 genetic polymorphisms, the metabolism of tamoxifen may be impacted by other factors with possible consequences on therapeutic outcome (efficacy and toxicity). This analysis focused on the pharmacokinetic (PK)-pharmacogenetic evaluation of tamoxifen in 730 patients with adjuvant breast cancer included in a prospective multicenter study. Plasma concentrations of tamoxifen and six major metabolites, the genotype for 63 single-nucleotide polymorphisms, and comedications were obtained 6 months after treatment initiation. Plasma concentrations of endoxifen were significantly associated with CYP2D6 diplotype (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text